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• Summarize the basic principles and strategies of an antimicrobial 
stewardship program
• Biomarkers and Rapid Diagnostics
• Describe appropriate antibiotic therapy strategies
Question
Which of the following is true?
1. Clinicians perceive antimicrobial overuse is a problem 
generally, but not locally
2. Other medical specialties responsible for overuse
3. Antimicrobial resistance is a macro problem but of 
limited concern at the bedside 
4. All of the above






(“No downside risk, so 
why not try?”)
New
Antibiotics:   Good when 




Consequences of inappropriate antibiotic use
Crisis in Infectious Diseases
Widespread antimicrobial drug resistance
Increasing number of patients who are 
immunosuppressed
Emergence of new pathogens
Reemergence of older pathogens
Decrease new drug development
Dysbiosis due to antimicrobial therapy
Clin Infect Dis 2017; 64:823-828
Collateral Damage of Antibiotic Use
• Average child receives 10-20 
courses of antibiotics before 
age 18
• Antibiotics affect our resident 
microbiota and may not fully 
recover after a course of 
antibiotics
• Overuse of antibiotics may be 
contributing to obesity, DM, 
IBD, allergies, and asthma
Nature 2011;476:393
Antimicrobial Resistance
• Increases mortality and morbidity
• Antibiotic-resistant infections have been estimated to 
cost the US healthcare system over $20 billion 
annually and over 35 billion in societal costs
Emerg Infect Dis 2001; 7:286
Arch Intern Med 2003; 163:972
Infect Control Hosp Epidemiol 2003; 24:642
Nat Rev Microb 2004; 2:251
Clin Infect Dis 2009; 49:1175-84
Practices That Promote Resistance
• Misuse of  antibiotic(s)
• Overuse of antibiotics in outpatient settings.
• Overuse of antibiotics in hospital settings.
• Poor compliance with regimens. 
• Use of antibiotics in animals. (80% of antibiotics sold to farms)
One Health Antibiotic Stewardship 
Collaborative
• Multi-partner initiative to address antibiotic use
• Inter-agency approach by government
• MDH, MN Board of Animal Health, MN Ag, 
Pollution Control Agency
• Stakeholders from academia, human and veterinary 
clinical practice, professional and industry 
associations, healthcare systems, producer 
organizations
Courtesy Dr Ruth Lynfield
Antibiotic Use Drives Resistance
http://www.cdc.gov/drugresistance/about.html



































Europe Canada Australia United States
% patients ≥ 1 antimicrobial
ECDC 2013 Point Prevalence Survey of HAI and antimicrobial use in European hospitals 2011-
2012,
Taylor et al Can J Infect Dis Med Microbiol. 2015 Mar-Apr; 26(2): 85–89.
Antimicrobial prescribing practice in Australian hospitals. December 2016. 
Magill et al JAMA 2014;312(14):1438-1446
Classes with highest increase in use US hospitals
Source: CDC. Antibiotic Use in the United States, 2017: Progress and Opportunities.
https://www.cdc.gov/getsmart/pdf/stewardship-report.pdf
Misuse of antibiotics
• An antibiotic is not used when it could 
improve healthUnderuse








Inappropriate use of antibiotics
Suboptimal or inadequate use
• administration is delayed in a critically ill patient, 
• choice of an antimicrobial with an unnecessarily broad spectrum 
or too narrow a spectrum
• dose is too high or too low
• duration is too long or too short
• treatment is not streamlined or changed when microbiological 
culture data become available
• use in patient with an allergy to the agent
• drug – drug interactions
• poor patient adherence to the prescribed treatment 
Inappropriate use in hospitals 
1.  CDC Get Smart for Healthcare in Hospitals and Long Term Care https://www.cdc.gov/getsmart/healthcare/
2. Antimicrobial prescribing practice in Australian hospitals. December 2016













Common Outpatient Clinical Syndromes and Overtreatment 
Infect Control Hosp Epidemiol 2015; 36:142-152 20
Pharyngitis 10%               >60%
Setting National Targets: 
Outpatient Antibiotic Prescribing
47 million unnecessary antibiotic 
prescriptions per year
Fleming-Dutra et al. JAMA 2016;315(17): 1864-1873. 
http://www.pewtrusts.org/~/media/assets/2016/05/antibioticuseinoutpatientsettings.pdf; CARB Action Plan
(CARB National Action Plan)
Outcomes of antibiotic misuse
• Development of resistant organisms, Clostridium 
difficile infections 
• Patient harm such as treatment failure adverse drug 
events and increased mortality 
• Increase healthcare and societal costs. 
It’s a Matter of Patient Safety
 Adverse events from antibiotics range from minor to severe 
• Side effects like rash or antibiotic-associated diarrhea
• Allergic reactions, including anaphylaxis (life-threatening)
 1 in 1000 antibiotic prescriptions leads to an emergency department (ER) visit for an adverse event
• 142,000 ER visits per year for antibiotic-associated adverse events
• Antibiotics are most common cause of drug-related emergency department visits for children
 Long-term consequences: growing evidence that antibiotics associated with chronic disease through 
disruption of the microbiota and microbiome
Shehab, et al. Clin Infect Dis. 2008 Sep 15;47(6):735-43.  Bourgeois, et al. Pediatrics. 2009;124(4):e744-50.
Linder. Clin Infect Dis. 2008 Sep 15;47(6):744-6.   Vangay, et al. Cell host & microbe 2015; 17(5): 553-564. 
Review on Antimicrobial Resistance (AMR), 2014.  Antimicrobial Resistance: Tackling 
a crisis for the health and wealth of nations. London, UK http://amr-review.org
Estimate: By 2050, 10 Million Deaths Attributed to AMR Every Year 
Costing World Economy $100 Trillion
GLOBAL DIMENSIONS
Regulatory
Stewardship Seats at the Table 







Core Elements for Antibiotic Stewardship Programs
http://www.cdc.gov/getsmart/healthcare/implementation/core-elements.html
CDC  Core Elements
1. Leadership commitment:  Dedicate necessary human, financial, 
and IT resources
2. Accountability: Appoint a single leader responsible for program 
outcomes-this is usually a physician
3. Drug expertise: Appoint a single pharmacist leader to support 
improved prescribing
4. Act: Take at least one prescribing improvement action, such as 
“antibiotic timeout”
5. Track: Monitor prescribing and antibiotic resistance patterns
6. Report: Regularly report to interdisciplinary team the prescribing 
and resistance patterns, and steps to improve
7. Educate: Offer team education about antibiotic resistance and 
improving prescribing practice
Centers for Disease Control and Prevention. MMWR. March 2014. 63; 194-200.
CDC’s Core Elements Adopted by
• The Joint Commission for their 
antibiotic stewardship 
standard
• DNV for their antibiotic 
stewardship standard
• CMS-funded Hospital 
Improvement Innovation 
Networks (HIINs) 
• AHRQ Comprehensive Unit-
based Safety Program 
(CUSP)




State Antibiotic Stewardship Legislative Policies
• California
• Senate Bills 1311 (2014) and 361 (2015) require antibiotic stewardship 
programs in all California hospitals and nursing homes
• Missouri
• Senate Bill 579 (2016) requires that all non-psychiatric hospitals
establish stewardship programs and report antibiotic use to CDC’s 
National Healthcare Safety Network (NHSN) Antimicrobial Use Option
Antimicrobial Stewardship  
program (ASP)
Basic principles and implementation strategies
The Challenge
• How to initiate and improve 
antibiotic stewardship efforts
• Proving that it works
• Clinical outcomes
• Decrease resistance
• Changing the antibiotic 
prescribing culture
• Hardwiring the process
• Continuing to show financial 
benefit to maintain funding 
and support of efforts
The Problem with Antimicrobial 
Stewardship
• Everyone thinks they know what it is
But who knows what it should be?
– Which strategies are most effective?
– How to assess their effectiveness?
Antimicrobial Stewardship: Definition
• A system of informatics, data collection, personnel, and 
policy/procedures which promotes the optimal selection, 
dosing, and duration of therapy for antimicrobial agents  
throughout the course of their use. 
• An effective antimicrobial stewardship program will limit 
inappropriate and excessive antimicrobial use, but more 
importantly improve and optimize therapy and clinical 
outcomes for the individual infected patient. 
Ohl CA. Seminar Infect Control 2001;1:210-21.
Ohl CA. J. Hosp Med. In press.
Dellit TH, et. al. Clin Infect Dis. 2007;44:159-177
Antimicrobial Stewardship: Goals
• Improve patient outcomes
• Optimize selection, dose and duration of Rx
• Reduce adverse drug events including secondary infection (e.g. C. 
difficile infection)
• Reduce morbidity and mortality
• Prevent or slow the emergence of antimicrobial resistance
• Reduce length of stay
• Reduce health care expenditures
MacDougall CM and Polk RE.  Clin Micro Rev 2005;18(4):638-56.
Ohl CA. J. Hosp Med. In press.





– What infection syndrome is being treated?
--Does the patient have an infection?
– Have appropriate diagnostic tests been collected? 
2. Right Drug
– Demonstrated effective per local epidemiology
– Safest




– Minimal duration undefined for many indications
– For most: resolution of systemic and improvement  in local  manifestations
5. Right De-escalation: change to narrowest spectrum/safest/least expensive regimen when:
– Justified by culture results (positive or negative)
– Clinical improvement (e.g., IV to PO switch)
Four Moments of Antibiotic Decision Making
1. Does my patient have an infection 
that requires antibiotics?
2. Have I ordered appropriate cultures 
before starting antibiotics? What 
empiric therapy should I initiate?
3. A day or more has passed.  Can I 
stop antibiotics? Can I narrow 
therapy or change from IV to oral 
therapy?
4. What duration of antibiotic therapy 
is needed for my patient's 
diagnosis?
AHRQ Safety Program for Improving Antibiotic Use. 2018. 
Obtain Cultures Prior to Starting Antibiotics!
• Develop a process to ensure cultures are properly and 
consistently ordered 
• Nursing to ensure safe/timely collection of specimens from 
appropriate source
• Develop processes to ensure cultures are properly and 
promptly transported and processed
ARHAI. Antimicrobial stewardship: “start smart-then focus”. Guidance for 
antimicrobial stewardship in hospitals (England). November, 2011.
Eur J Clin Microbiol Infect Dis. 2009;28(2009):1447-1456.
CDC. Core Elements of Hospital Antibiotic Stewardship Programs. 2014.
Am J Infect Control. 2013;41(2013):365-367. 
Clinical Pearl: Appropriate Specimen 
Collection and Cultures
• Wounds
• Recommend against superficial swab, likely colonizing organisms
• Preferred samples are pus and tissue 
• Surgical wounds – recommend contacting MD prior to culture collection, consider 
wound care consult if available for cleansing/debridement prior to sample
• Blood cultures
• Separate peripheral venipunctures using aseptic technique are preferred
• Drawing blood for cultures from indwelling catheters should be avoided unless 
the catheter is thought to be the source of bacteremia
• Label specimen and collection site and time
• Urine
• Evaluation of the patient’s symptoms is critical before ordering urine culture
• Screening for asymptomatic bacteriuria (ABU) is not recommended except in 
pregnancy and before an invasive urological procedure
• A urinalysis should be performed before a urine culture is ordered.  Urine with 
>10 WBC/HPF with symptoms should have a urine culture if patient has 
symptoms.  
Culture results guide better patient care decisions
Clinical Pearl: Appropriate Specimen Collection and Cultures (2)
• Stool for C. difficile
• clinically significant diarrhea is defined as 3 or more unformed stools samples 
within 24 hours
• Only watery or unformed loose stool should be submitted (Bristol 6 or 7) 
• If patient has been on laxatives in the last 48 hours cancel order and allow at 
least 48 hours without laxatives to reassess
• Testing to evaluate for cure is not recommended.
• PCR does not distinguish colonization versus infection, therefore indications 
for testing are very important.
MAXIMIZE 
COVERAGE





Choice of Empiric Agent








Selection based on potential for resistance





Physician writes order 
for “Restricted Drug”
Order arrives in pharmacy, 
pharmacist informs the 
physician and primary nurse 
that the drug is 
“restricted”/”Not part of the 
pathway”/”non-formulary”
Prescribing Physician and the 
“GATE KEEPER” converse




• Direct control over 
antimicrobial use










relationship (loss of 
autonomy)
• Therapy may be delayed
• Manipulation of the 
system
• ID physicians often 
exempt
• Effectiveness in 
decreasing resistance is 
less clear
• No impact on de-
escalation or duration





At a later date, antibiotics are 
reviewed by interdisciplinary 
team
(Targeted list of antibiotics, 
C/S mismatches, ICU patients, 
duration)
1.)  Antibiotic 
Change/Continued 
based on Practice 
Guidelines
2.)  Prescribing 
physician contacted and 
recommendation made
Prospective Audit and Feedback
• Advantages




• Patient information 









• Identification of 
patients may require 
computer support
• Prescribers may be 
reluctant to change 
therapy if the patient is 
doing well





• Protocols to guide therapy for a given infection







– Form of education
• Disadvantages
– Adherence is usually 
voluntary
– “Cookbook medicine”
– Maintenance is 
required
*Guidelines may not be appropriate for all situations. Decisions should be based on 
clinical judgment and consideration for individual patients.
De-Escalation: Goals
• Changing from a broad-spectrum antibiotic to one with a narrower spectrum if 
appropriate
• Eliminate overlapping or combination therapy targeting causative organism or
• Stopping antimicrobial therapy when a non-infectious etiology most likely
• Administer antimicrobial therapy for the correct duration
• Decrease antimicrobial exposure → reduce adverse events
• Cost savings
De-escalation Timeline
























• Decrease number of agents and/or spectrum of activity as appropriate in 
response to culture results and clinical outcomes
• Optimizing initial therapy may oppose steps to limit use of broad-spectrum 
agents
• De-escalation recognizes both aspects
• Advantages
– Allows initial use of broad-
spectrum therapy
– Narrows therapy when 
appropriate
– Improves outcomes
– Reduces adverse events
– May influence future 
prescribing behavior




– Prescribers may be reluctant 
to change therapy if the 
patient is doing well




The most common reasons for not de-escalating:
• Lack of conclusive microbiology
• Continued use of broad-spectrum antimicrobial therapy
• Diagnostic uncertainty
• Treatment of fever, colonization and/or contamination
• Insecurity 
• Treatment of noninfectious syndrome associated with fever 
• Duration longer than necessary leading to increase adverse 
events 
• Highlight duration of therapy for broad-spectrum antibiotics
• Engage all members of the interdisciplinary healthcare team in monitoring
Antibiotic Time Out
• Trigger tool to stop and 
reassess antibiotic therapy
• Targeted at all providers for 
Med/Surg patients 
• Guided assessment at 72 hrs 
• Treatment duration 
recommendations included 
for key infections
Duration: Avoid automatic 10-14 Day Courses
• New Evidence for Duration of Therapy
– Uncomplicated urinary tract infection: 3-5 days1
– Community-acquired pneumonia: 3-7 days2
– Ventilator-associated pneumonia: 8 days3
– CR-BSI Coagulase-negative staphylococci: 5-7 days4
– Acute Hem Osteomyelitis in children-21 days5
– Meningococcal meningitis-7 days6
– Uncomplicated secondary peritonitis with source control: 4-7 days7
– Uncomplicated SSTI 5 days8
1. Clin Infect Dis 1999; 29:745-758
2. Clin Infect Dis 2007; 44:S27-72
3. JAMA 2003; 290:2588-2598
4. Clin Infect Dis 2009; 49:1-45
5. Pediatr Infect Dis 2010; 29:1123-1128
6. N Engl J Med 1997; 336:708-716
7. Clin Infect Dis 2010: 50:133-164
8. Arch Intern Med 2004; 164:1669-1674
Case
This is a 46 year old female admitted with hypotension, 
fever, and flank pain.  She has no underlying medical or 
urologic problems. Her urine showed pyuria and 
bacteriuria, the peripheral WBC was 16,000/mm3.  She 
was admitted to the ICU and empirically started on 
_______.





And Now the Rest of the Story
She was admitted to the ICU and started on cefepime.  A PICC line was inserted. By 
day 2, she stabilized and was transferred to the floor.  Her urine and blood grew E. 
coli sensitive to all tested antibiotics except ampicillin.  The results were not 
available until after she was transferred to the floor. She was continued on 
cefepime.  On day 7, she spiked a new fever.  Blood cultures were drawn and 
grew__________. Antibiotics were changed to _________.  On day 12 her WBC 
increased to 30,000/mm3 and she reported unformed stools.  Your 
diagnosis_____________





In press Am J Infect Control
ASP Phase 1 Foundational
• MD/ PharmD Champion
• Multidisciplinary team
• Gap Assessment
• Assess staff resources
• Competency/Training Planning
• Communication Plan for facility 
• CEO support for AMP by 
approval of gap and action plan
• Selecting Physician 
Champion
• Complete gap assessment 
and action plan as a team
• Determine staffing needs to 
adequately resource AMP 
activities
• Create competency/training 
plan for all disciplines based 
on current knowledge and 
involvement
• Invite CEO to AMP team 
meeting to discuss plan, 
resources, and support
The establishment of a well supported, multidisciplinary ASP 
infrastructure ensures an ASP is sustainably integrated into 
facility practices rather than dependent on a single person
Antimicrobial Stewardship Team

































Modified Clin lnfect Dis 2007;44:159-177.
*based on local resources
Nursing
Physician To Do List
• Select local physician champion
• Develop an effective antimicrobial stewardship team
• Education the medical staff and administration about 
the urgency and value of an effective antimicrobial 
stewardship team
• Assure that microbiology is aware of how to detect 
new resistance mechanisms (e.g. CREs, NDM1) and 
new CLSI break points

Infectious Diseases Physicians: Leading the Way in
Antimicrobial Stewardship 
Pharmacy Leadership
• Pharmacy leadership is consistently identified as a must for 
stewardship in hospitals.
• Pharmacists often play a lead role in implementing improvement 
interventions and monitoring antibiotic use. Should have some 
training in infectious diseases. (e.g. MAD-ID, SIDP, SHEA)
• Many programs are co-lead by a physician and pharmacist.
Role of Infection Prevention
• Timely communication to team when MDROs are 
identified
• Prevention of MDRO in health care facilities
• Monitor trends in antimicrobial resistance
• Educate team about NHSN definitions of HAIs
• Collaborate with microbiology, pharmacy, medical 




Obtain Cultures Prior to Starting Antibiotics!
• Develop a process to ensure cultures are properly and 
consistently ordered-cultures should have an indication 
• Develop a process to ensure cultures are properly and 
consistently obtained
• Develop processes to ensure cultures are properly and 
promptly transported and processed
• Develop standards for and assess reliability of processes 
for ordering and obtaining a culture 
• Link molecular diagnostics to stewardship
Are nurses underutilized in ASP?
RN PharmD ID-MD
Patient triage and isolation X
Accurate allergy history X X
Timely antibiotic initiation X X
Daily progress monitor and report X X X
Preliminary antibiotic dosing X X X
Adverse event monitoring X X
Change in patient condition X X
IV to PO adjustment X X X
Patient education X X X
Olans RN et al. Clin Infect Dis. 2016; 62:84-89
Defining a Role for Nursing Education in Staff Nurse Participation in Antimicrobial 
Stewardship.  Olans RD et al. J Contin Educ Nurs. 2015; 46:318-21.
“Identified a need for more education and also an interest in the area for practicing 
nurses.”
Evidence-based guidelines for implementation and measurement of 
antibiotic stewardship interventions in inpatient populations including 
long-term care were prepared by a multidisciplinary expert panel of the 
Infectious Diseases Society of America and the Society for Healthcare 
Epidemiology of America. The panel included clinicians and investigators 
representing internal medicine, emergency medicine, microbiology, 
critical care, surgery, epidemiology, pharmacy, and adult and pediatric 
infectious diseases specialties. These recommendations address the best 
approaches for antibiotic stewardship programs to influence the optimal 
use of antibiotics
Infection Prevention and EpidemiologyClin Infect Dis 2016;62(10):e51–e77
Suggested Measures
Modified Curr Infect Dis Rep 2014; 16:433
Suggested Measures continued
Modified Curr Infect Dis Rep 2014; 16:433
ASP Phase 2
• Antimicrobial formulary review
• Review metrics (e.g. DOT, CDI, expenditures)
• Review CAP and SCIP core measure
• Microbiology 
• CLSI susceptibility reporting
• Review new CLSI breakpoints
• Appropriate use of microbiology document 
with emphasis on obtaining appropriate 
cultures before starting antimicrobial 




• IV to PO
• Associated with clinical and 
economic benefit
• Review facility by-laws  and state 
scope of practice for automatic 
interchanges
• P&T and Med Exec approval
• Many institutions have these 
activities implemented (CAP/SCIP)
• Routine IV to PO/ Renal Dosing
ASP Phase 3
• Kinetic dosing
• Vanc and AG
• Prolonged infusion for pipercillin/tazobactam and 
carbapenems
• Approve institutional guidelines
• CAP, HAP, UTI and ABU, MRSA, VAP, intra-abdominal, 
surviving sepsis, C. difficile
• Timely and appropriate use of antibiotics based on 
approved institutional guidelines and local antibiograms
• Optimize duration based on evidence-based peer review     
publications
• Evaluate use agents based on local needs (front/back-end 
approach)
• Suggested drugs: daptomycin, linezolid, 
echinocandins, tigecycline, and carbapenems
• Clinical pharmacy rounding with team
• Involve nursing staff early in 
extended infusion work
• Meropenem and P/T 
prolonged infusion 
recommendation can be 
combined with formulary 
change to P&T
• Evaluate ability of pharmacist 
to cover drug regimen 
reviews and rounding 
consistently
ASP Phase 4
• De-escalation “72 hour time-out”
• Suggestions: review charts with positive 
blood cultures, 3 or more antibiotics for 
≥72 hours, drug-bug mismatches, or 
antibiotics without a positive culture, 
duration
• Review and/or implement rapid diagnostics, 
point of care testing, and biomarkers (PCT)for 
appropriate use
• Ongoing antibiogram development (e.g. unit 
specific)
• Report approved metrics to all stakeholders 
on a regular basis
•Clinical decision support/CPOE
• Overlap will occur with 
various phases. 
• Expectation is for facility 
to complete elements of 
each phase in a timely 
manner.  
• Advanced programs can 
start on other phases 
before the suggested 
timelines.
• Synergize ASP with Core 
Measures and Sepsis 
Programs
• Provide guidance on use 












Rapid Diagnostic Tests 










Rapid Diagnostic Tests (2)
• Culture dependent
• Rapid biochemical identification
• Proteomic identification (MALDI-TOF)
• BCID microarrays, nanoparticle, and PNA-FISH
• Rapid phenotypic AST
• Detection of selected resistance genes
Rapid Diagnostic Tests (3) 
• Culture independent
• Direct antigen detection tests
• Single target or limited multiplex NAATs
• In lab and now POCTs
• Syndromic multiplex panels for BSI, GI, RT, and CNS 
infections
• Direct detection of BSI by PCR/T2 MRI and PCR/ESI/MS  
CASE 
This is a 54 year-old female readmitted to the hospital for probably 
deep sternal SSI.  Three weeks earlier she underwent a CAB, MV 
repair, and an AVR.  She received “appropriate” surgical prophylaxis.  
She is a known diabetic.
CASE  Continued (2)
• On readmission she was febrile (102o), BP 90/60, P-120;
• Lungs--decreased breath sounds on left, no rubs, --
purulence from lower sternum.  
• White count was 18,000 with 15% bands, lactate 3.1, creat
2.1, blood cultures were drawn 
Case continued(3)
•ID was called in ED
•Gram stain was performed which showed—
rapid diagnostic test performed within 2 
hours of arrival to ED






• Vancomycin and piperacillin/tazobactam by ED physician 
was started.  ID physician discontinued 
piperacillin/tazobactam.
• At 12 hours blood cultures were positive for gram-
positive cocci in clusters
• Culture from sternum was identified at S aureus the 
next morning sensitivities pending 
• Patient was taken to surgery for sternal debridement
• TEE indicated a vegetation on her AV
Scenario #1 Traditional Method --
Suspected Infection
• Fluid or Tissue Sample
• Gram’s Stain
• Bacteria present?  If so, Gram - or +
• Results in minutes
• Sample incubated in culture media
• Usually 24 hours for growth
• Biochemical testing to determine organism
• Minutes to 24 hours
• Susceptibility testing
• Another 24-48 hours
• At 48 hours, susceptibilities revealed MSSA
Scenario #2 Rapid Molecular Methods
• Technologies available
• Polymerase chain reaction (PCR)
• Multiplex PCR
• Nanoparticle Probe Technology
• Matrix-Assisted Laser Desorption/Ionization Time-of-
Flight Mass Spectrometry (MALDI-TOF MS)
• From blood culture MALDI confirmed S aureus and PCR 
indicated this was a MSSA within 4 hours of + blood 
culture.
• Total time 16 hours vs 48 hours by traditional methods
What would you do now?
Does it matter since vancomycin covers both MSSA and 
MRSA?

























30-Day In Hospital Mortality 
BMC Inf Dis. 2011; 11: 279-85.
*Statistically significant
90









Why does Culture Matter?
• Safety culture influences the effectiveness of other safety 
and quality interventions
• Can enhance or inhibit effects of other interventions
• Safety culture can change through intervention
• Best evidence so far for culture interventions that use 
multiple components (e.g.: CUSP, Positive Deviance)
Haynes et al., 2011; Morello et al., 2012;  Van Nord et al., 
2010; Weaver et al. Ann Intern Med. 2013;158:369-374.
Physician Barriers
• Physician accountability and acceptance of need for improvement
• Misperceptions
• Misalignment of incentives
• Lack of definition of appropriate use of antimicrobial agents
• Lack of standardized, risk-adjusted measures
• Adaptive/behavioral changes needed to change prescribing practices
Surviving Sepsis Campaign Mandate
Treat first and then evaluate later
Intensive Care Med 2018; 44:925-928
Inconvenient Truths
• High rate of overdiagnosis
• Approach promotes excess antimicrobial use and increases unintended consequences
• C difficile infections
• Acute kidney injury and other side effects (e.g. hepatitis, rash, cytopenias)
• Missed culture opportunities (antibiotics administered before appropriate cultures obtained) 
• Selection for MDROs
• Alteration of microbiome-dysbiosis
• Less than 60% of patients admitted to ICU with diagnosis of “sepsis” are confirmed (Crit
Care Med 2015; 19:319)
• Time to antibiotics matters for septic shock, but evidence is less convincing for patients 
with possible sepsis without shock
• Two recent studies confirmed association between delay in antimicrobial administration and 
mortality in patients with septic shock but little or no association for patients without shock (N Engl J 
Med 2017; 376:2235-2244; Am J Respir Crit Care Med 2017; 196:856-863)
• Randomized trial of antibiotics administered in the ambulance versus administered in ED for 
patients with suspected sepsis found mortality was the same in both groups.  More than 90% 
of patients enrolled in study had infection alone or sepsis without shock. (Lancet Respir Med 2018; 
6:40-50)
Key Elements for Successful ASP
• Establish compelling need and goals for ASP
• Senior leadership support
• Effective local physician champion
• Adequate resources and competencies (pharmacy, infection preventionist [IP], 
microbiology, information technology [IT])
• Primary objectives: optimize clinical outcomes and reduce adverse events, not 
reduce costs
• Good teamwork
• Agreed upon process and outcome measures
• ASP should be across the continuum of care

• Indicators of High Performing Teams
• A high degree of interaction and communication among 
all members with mutual respect
• The team directs energy towards the team vision and 
goals and less energy towards individual’s  own agenda
• A sense of common ownership
• Commitment and trust
• Members feel great personal satisfaction from 
belonging to the team
• Team members share loyalty and group identification
Stewardship is a Team Sport
SUCCESS IS NOT FINAL,
FAILURE IS NOT FATAL:
IT IS THE COURAGE TO 
CONTINUE THAT COUNTS
Winston Churchill

